Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
EAN 2022
ESOC 2022
AAN 2022
CONy 2022
AD/PD 2022
World Sleep 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Rituximab
8:46
Deep learning can predict treatment response in patients with progressive MS
Jean-Pierre Falet
• 22 Mar 2022
3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana
• 28 Feb 2022
1:57
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs
Celia Oreja-Guevara
• 24 Feb 2022
2:25
The importance of assessing autoreactive T-cell responses in MS
Olivia Thomas
• 21 Oct 2021
7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico
• 30 Sep 2021
7:22
COVID-19 vaccination in patients with MS
Maria Pia Sormani
• 13 Oct 2021
1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara
• 14 Oct 2021
1:14
How does ublituximab compare to other anti-CD20 mAbs?
Lawrence Steinman
• 15 Oct 2021
6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara
• 14 Oct 2021
9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì
• 22 Jun 2021
3:47
Update on pediatric NMOSD and MOGAD
Brenda Banwell
• 26 Apr 2021
4:18
Determining the optimal treatment strategy in MS
Tanuja Chitnis
• 23 Feb 2021
